PURPOSE

Doxorubicin (DOX) is a chemotherapeutic medication broadly used to treat diverse cancers. However, chronic DOX chemotherapy can cause myotoxicity and muscle atrophy. Endurance exercise (EXE) is used to prevent negative muscle excitation. Based on emerging evidence, this study investigated the challenges that occur in skeletal muscle quantity, quality, and metabolic determinants through autophagy, myogenic regulatory factors (MRF), antioxidant enzymes, and both the AMPK and AKT/mTOR pathways.

METHODS

Male C57BL/6J adult mice were divided into four groups after one week of acclimation: sedentary (SED) plus saline (SAL)-receiving (SED-SAL), EXE plus SAL-receiving (EXE-SAL), SED plus DOX-receiving (SED-DOX), and EXE plus DOX-receiving (EXEDOX) groups. All mice were intraperitoneally inoculated with either SAL or DOX (5 mg/kg, every 2 weeks) for 8 weeks, while a treadmill running EXE was performed. Body weight, muscle weight, and muscle strength were measured, and the red portions of the gastrocnemius muscle were excised for biochemical analysis.

RESULTS

Chronic DOX administration deteriorated body composition by decreasing body and absolute muscle weights, whereas EXE reinforced a grip strength per body weight. Although DOX inhibited BECN1 expression, EXE enhanced CS, LC3-I, LC3-II, and LAMP levels. Moreover, DOX did not interrupt MRF functions, but EXE improved MYOD without altering SOD1 or SOD2 expression. However, neither the AMPK nor the AKT/mTOR signaling pathways were associated with either DOX-receiving or EXE training.

CONCLUSION

DOX chemotherapy-induced muscle wasting is associated with autophagy dysregulation. However, long-term aerobic EXE training enhances muscular strength with an increase in mitochondrial oxidative capacity, lysosome formation, and myogenic differentiation.